Chemo before surgery for potentially resectable pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests 6 cycles of a chemotherapy combination called modified FOLFIRINOX before surgery for pancreatic cancer that can potentially be removed. The goal is to see if this approach improves outcomes for patients who might be candidates for another study called PANACHE02.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic adenocarcinoma (a type of pancreatic cancer) confirmed by a biopsy.
- Your tumor is considered potentially removable by surgery, as determined by a team of doctors after reviewing a special CT scan.
- You have not received chemotherapy before.
- You are 18 years or older.
- You are in good general health (ECOG performance status 0 or 1, meaning you can carry out normal activities without help).
- Your blood counts and kidney function are within certain limits (neutrophils, platelets, creatinine clearance, hemoglobin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving different types of extra chemo (after surgery) based on the stage of your cancer can help prevent it from coming back. It's for people with pancreatic cancer who already had chemo and surgery.
This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This trial studies giving chemo and hydroxychloroquine before surgery for resectable pancreatic cancer. The goal is to shrink the tumor and improve the chances of successful removal.
This Phase 2 trial tests giving chemotherapy plus pembrolizumab (an immunotherapy) before surgery, to shrink or control potentially removable pancreatic cancer. The goal is to improve outcomes while making sure the cancer can still be safely removed by surgery.
Hear when a new Resectable Pancreatic Duct Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.